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Eczema is very common and increasing in prevalence. Prospective studies investigating environmental and
genetic risk factors for eczema in a birth cohort are lacking. We evaluated risk factors that may promote
development of childhood eczema in the Cincinnati Childhood Allergy and Air Pollution Study (CCAAPS) birth
cohort (n¼ 762) of infants with at least one atopic parent. Objective environmental exposure data were available
for each participant. At annual physical examinations, children underwent skin prick tests (SPTs), eczema was
diagnosed by a clinician, and DNA was collected. Among Caucasian children, 39% developed eczema by age 3.
Children with a pet dog were significantly less likely to have eczema at age one (odds ratio (OR)¼ 0.62, 95%
confidence interval (CI): 0.40–0.97) or at both ages 2 and 3 (OR¼ 0.54, 95% CI: 0.30–0.97). This finding was most
significant among children carrying the CD14–159C/T CC genotype. Carriers of the CD14–159C/T and IL4Ra I75V
single-nucleotide polymorphisms (SNPs) had an increased risk of eczema at both ages 2 and 3 (OR¼ 3.44, 95%
CI: 1.56–7.57), especially among children who were SPTþ . These results provide new insights into the
pathogenesis of eczema in high-risk children and support a protective role for early exposure to dog, especially
among those carrying the CD14–159C/T SNP. The results also demonstrate a susceptibility effect of the
combination of CD14 and IL4Ra SNPs with eczema.
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INTRODUCTION
The prevalence of eczema has nearly tripled in industrialized
countries during the past three decades, and recent pre-
valence estimates demonstrate that 15–30% of children are
affected (Williams and Flohr, 2006). In the United States, the
projected health care costs due to eczema range from $0.9 to
$3.8 billion (Ellis et al., 2002). The hallmarks of eczema are a
chronic, relapsing form of skin inflammation, a disturbance of
epidermal-barrier function, and IgE-mediated sensitization to
food and environmental allergens (Bieber, 2008). It is often
the first step of the ‘‘atopic march’’ that may lead to the
development of allergic rhinitis and asthma (Leung et al.,
2004). Thus, early identification of risk factors and possible
intervention strategies may lead to the discovery of measures
that attenuate later expression of allergic diseases.
Eczema results from complex interactions between host
(genetic susceptibility and skin barrier dysfunction) and
environmental factors (allergens, irritants, and infectious
agents). Genome-wide scans have identified several possible
eczema loci on chromosomes 3q21.11, 16q, 17q25, 20p,12,
and 3p26.13, and most notably 1q21, which harbors a family
of epithelium-related genes called the epidermal differentia-
tion complex (Cookson, 2004; Palmer and Cardon, 2005).
Thus, there are two predominant groups of genes that have
been associated with eczema: genes encoding epidermal
structural proteins and genes encoding major elements of the
immune system, especially those important in allergic
sensitization (Bieber, 2008).
In patients with early-onset eczema, IgE-mediated sensi-
tization often occurs several weeks or months after the lesions
appear, suggesting that the skin is the site of sensitization
(Spergel and Paller, 2003). Indeed, in animal models,
repeated epidermal challenge with antigen induces specific
IgE and eczematous lesions at the application site (Spergel
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et al., 1998). Recently, a unifying hypothesis (Bieber, 2008)
has been proposed and suggests that the natural history of
eczema has three phases including (1) an initial non-atopic
phase in early infancy, when sensitization has not yet
occurred; (2) in 60–80% of patients, genetic predisposition
results in the induction of IgE-mediated sensitization to foods
and/or environmental allergens leading to eczema; and (3)
scratching damages skin cells releasing autoantigens and
leading to IgE autoantibodies.
Food and inhalant allergens, as well as microbial agents,
contribute to eczema (Leung et al., 2004); however, the
environmental and genetic factors that protect/contribute
remain largely unclear. In order to identify environmental
and genetic factors that contribute to the development of
eczema in early childhood, we studied a birth cohort of over
762 high-risk infants born to at least one atopic parent
followed prospectively as part of Cincinnati Childhood
Allergy and Air Pollution Study (CCAAPS).
RESULTS
Participant characteristics and environmental exposures
The Cincinnati Childhood Allergy and Air Pollution Study
is comprised of 54.3% males, 76.6% Caucasians, 19.8%
African-Americans, and 3.8% are bi-racial or other. Since the
genotype frequencies of several studied single-nucleotide
polymorphisms (SNPs) were significantly different between
Caucasians and African-Americans, only Caucasians were
evaluated as power was too low for other racial groups.
Figure 1 describes the eczema status and skin prick test
(SPT) results among Caucasian children at ages 1–3. Eczema
was present in 9.7% of children and increased to 29.1 and
26.7% at ages 2 and 3, respectively. The proportion that was
SPTþ for one or more allergens were 28.1, 39.7, and 42.0%
at ages 1, 2 and 3, respectively. The percentage of children
who were SPTþ to aeroallergens alone increased over time,
13.9, 31.1, and 36.0%, while those who were SPTþ to food
antigens alone decreased, 9.7, 2.5, and 1.2%, respectively.
The percentage did not change appreciably for children who
were SPT þ to both aero- and food allergens, with 4.5, 6.1,
and 4.8% positive at ages 1, 2 and 3, respectively (data not
shown).
A summary of environmental exposures is displayed
in Table 1. At enrollment, almost 30% were exposed to
environmental tobacco smoke in the home. Dog(s) were
present in 38% of the homes, while 28% reported having at
least one cat. During the first year of life, almost 60% of
homes had visible mold, with 6% in the high mold category.
Diesel exhaust particles (DEPs) exposure ranged from
0.23 mgm3 to 0.88mgm3; high DEP was defined as the
top quartile. Endotoxin levels obtained from home dust
samples ranged from 6.0 to 800.0 EUmg1, and the
geometric mean was 73.2 EUmg1.
Environmental exposures, SPT results, and eczema
The associations between SPT results, environmental expo-
sures, and eczema outcomes are displayed in Table 2.
Children who were SPTþ to at least one aeroallergen during
the first three years of life were over two times more likely to
have eczema by age 3 (OR¼ 2.69, 95% confidence interval
(CI): 1.80–4.01, Po0.001) and almost nine times more likely
to have eczema at both ages 2 and 3 (OR¼8.78, 95% CI:
3.87–19.92, Po0.001). Children with persistent aeroallergen
sensitization were over five times more likely to have eczema
at both ages 2 and 3 (OR¼5.25, 95% CI: 3.00–9.19,






















Figure 1. Summary of eczema and SPT results of Caucasians in the CCAAPS
cohort at ages 1–3.
Table 1. Summary of environmental exposure status
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No mold 222 40.8
Low mold 290 53.3
High mold 32 5.9
High DEP (X0.44 mgm3) 144 24.9






CCAAPS, Cincinnati Childhood Allergy and Air Pollution Study; DEP,
diesel exhaust particle; ETS, environmental tobacco smoke.
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positive to aeroallergens only and negative to food (n¼470)
yielded similar results (OR¼5.50, 95% CI: 2.73–11.05; data
not shown). Children sensitized to foods were significantly
more likely to develop eczema at age 1, by age 3, and at both
ages 2 and 3 (Po0.001).
Children whose parents reported having a pet dog at
enrollment were over 50% less likely to have eczema at age
one (OR¼0.49, 95% CI: 0.25–0.95, P¼0.04). Children
who had a pet dog had nearly a two-fold decreased risk of
eczema at both ages 2 and 3 (OR¼ 0.54, 95% CI: 0.30–0.97,
P¼0.04). To ensure there was no bias in dog exposures
related to parental history of eczema, we examined this
relationship and found no effect. There was an increased risk
for eczema at age 1 with high DEP exposure (OR¼1.89, 95%
CI: 1.05–3.04, P¼0.03). For all other environmental ex-
posures, no significant association was observed with eczema
during the first three years of life.
Association of CD14 and IL-4Ra with eczema
Seven SNPs were genotyped in four atopy-related genes.
These genes were chosen because more than 10 independent
studies (Ober and Hoffjan, 2006) have shown associations
with atopy or asthma phenotypes, and are biologically
relevant by altering gene expression or function.
The associations of the CD14 C-159T and IL4Ra I75V
SNPs with eczema and SPTþ are summarized in Table 3.
The genotype CC of the SNP CD14 C-159T significantly
increased the risk of eczema at both ages 2 and 3 (OR¼3.01
95% CI: 1.04–8.68, P¼ 0.01), and this trend was also
observed for eczema at age 1 and eczema development by
age 3. An increased risk of eczema by age 3 was also
observed with the IV genotype of IL4Ra I75V (OR¼1.77,
95% CI: 1.07–2.96, P¼0.03). This same trend was observed
for all three eczema outcomes for both the IV and VV
genotypes of the IL4Ra SNP, so these two genotypes were
then combined. Children who carried both the CC and IV/VV
variants (n¼ 64) were over two times more likely to develop
eczema by age 3 (OR¼ 2.24, 95% CI: 1.27–3.94, Po0.01),
and were over three times more likely to have eczema at both
ages 2 and 3 (OR¼3.44 95% CI: 1.56–7.57, Po0.01). The
association of the combination of these two SNPs with
eczema remained significant even after Bonferroni correc-
tion. There were no significant associations observed with
any of the other SNPs and eczema. The association of these
SNPs with a positive SPT response was also examined. The
combination of the two SNPs (CD14-159C/T and IL4Ra I75V)
was not significantly associated with SPTþ , but showed a
similar trend as observed with eczema (26.1% vs 17.3%,
P¼0.10; data not shown).
Since allergen sensitization plays a critical role in eczema
development, we evaluated the subgroup of children who
were SPTþ and had eczema. Strikingly, children with SPTþ
and eczema by age 3 were over three times more likely to
have the genotype combination of CD14 C-159T CC and
IL4Ra (IVþVV) compared with children without eczema
who were SPT (OR¼3.01, 95% CI: 1.37–6.63, Po0.01;
Table 2. Unadjusted associations between eczema, SPT testing, and environmental exposures among CCAAPS
Caucasians
Eczema at age 1 Eczema by age 3 Eczema at ages 2 and 3
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
SPT+ 1.89 (0.93–3.81) 0.07 2.69 (1.80–4.01) 0.01 8.78 (3.87–19.92) o0.001
Persistent aeroallergen sensitization 1.51 (0.84–2.93) 0.22 2.38 (1.62–3.48) o0.001 5.25 (3.00–9.19) o0.001
SPT+ to food 3.58 (2.00–6.44) o0.001 3.38 (2.20–5.19) o0.001 7.0 (3.37–14.48) o0.001
Dog exposure 0.49 (0.25–0.95) 0.04 0.75 (0.51–1.06) 0.10 0.54 (0.30–0.97) 0.04
Cat exposure 0.58 (0.26–1.26) 0.17 0.87 (0.57–1.31) 0.49 1.04 (0.55–1.97) 0.89
High DEP 1.89 (1.05–3.04) 0.03 1.05 (0.71–1.55) 0.80 0.62 (0.31–1.22) 0.17
Mold exposure
None Ref. Ref. Ref.
Low 0.98 (0.54–1.79) 0.95 1.34 (0.93–1.92) 0.12 1.43 (0.83–2.48) 0.20
High 1.48 (0.47–4.66) 0.50 1.31 (0.61–2.81) 0.48 0.29 (0.04–2.28) 0.24
ETS
None Ref. Ref. Ref.
1–19 cigarettes per day 0.80 (0.38–1.7) 0.56 1.10 (0.72–1.69) 0.65 1.42 (0.73–2.80) 0.31
20+ cigarettes per day 0.77 (0.23–2.61) 0.67 0.82 (0.42–1.61) 0.56 0.86 (0.28–2.65) 0.79
CCAAPS, Cincinnati Childhood Allergy and Air Pollution Study; CI, confidence interval; DEP, diesel exhaust particle; ETS, environmental tobacco smoke;
OR, odds ratio; SPT, skin prick test.
Bold indicates Po0.05.
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data not shown). The increased prevalence of this genotype
combination between CD14 and IL4Ra among the SPTþ
children with eczema supports the potential of combined
genetic susceptibility to allergic disease and eczema.
CD14-159C/T and dog exposure association with eczema
and SPTþ
The associations of CD14 C-159T and dog exposure are
displayed in Figure 2a-b. Of the 148 Caucasian children who
had eczema at age 2, about half, 72 (48.6%), also had
eczema at age 3. We evaluated the individual and combined
effects of the CT and TT genotypes with dog exposure
since they both confer protection in our data (see Table 1 and
Table 3). The CT/TT genotype of CD14-159C/T was
significantly associated with a 38% reduction in risk of
eczema by age 3 (OR¼ 0.62, 95% CI: 0.40–0.97, P¼0.03)
and an even stronger reduced risk (57%) of eczema at
both ages 2 and 3 (OR¼0.43, 95% CI: 0.23–0.82, P¼0.01).
Dog exposure also reduced the risk of eczema at age 1
(OR¼0.49, 95% CI: 0.25–0.95, P¼ 0.04) as well as eczema
at both ages 2 and 3 (OR¼ 0.54, 95% CI: 0.30–0.97),
P¼0.04). This same protective trend was observed with
eczema development by age 3 (P¼ 0.10). When genetic and
environmental factors that conferred decreased eczema risk
were combined, an even stronger effect was observed.
Children with the CD14 C-159T CT or TT genotype who
lived in homes with dog(s) were almost 60% less likely to
have eczema by age 3 (OR¼0.56, 95% CI: 0.33–0.96,
P¼0.04) and eczema at both ages 2 and 3 (OR¼0.36, 95%
CI: 0.14–0.89, P¼0.03) compared with all other children
(children with the CC genotype and/or no dog exposure; data
not shown). This association was even stronger for atopic
eczema at both ages 2 and 3 (OR¼ 0.33, 95% CI 0.12–0.89,
P¼0.03; data not shown). Thus, dog exposure in early life
and the CT or TT genotype of CD14-159C/T SNP both
provide protection from the development of eczema in young
children. There were no significant associations between
genetics and DEP exposure with eczema risk.
Similarly, an analysis with persistent SPTþ as the
outcome was evaluated. Of the 207 Caucasian children
who were SPTþ at age 2, 126 (60.9%) remained SPTþ at
age 3. There were no significant associations found between
CD14 C-589T and dog exposure with persistent allergen
sensitization.
Adjusted models of eczema
We also evaluated models of the three eczema outcomes
including dog exposure, persistent aeroallergen sensitization,
food sensitization, and the CD14 C-159T and IL4Ra I75V
SNPs, adjusted for gender and parental history of eczema
(data not shown). Persistent aeroallergen sensitization was
the most significant predictor of eczema at both ages 2 and 3
(OR¼14.39, 95% CI 4.40–47.10, Po0.001), and there was a
significant interaction between persistent aeroallergen sensi-
tization and the CD14-159T CC genotype (OR¼4.66, 95%
CI 1.41–15.38, P¼ 0.01). This indicates that children who
carry the SNP and are persistently sensitized to aeroallergens
are at the greatest risk for persistent eczema, suggesting a role
for innate immunity. We observed the same significant
associations in the model of eczema development by age 3.
When stratified by pet dog ownership, the interaction
between persistent aeroallergen sensitization and the CD14
CC genotype remains significant only for children without a
pet dog presumably because this was a protective factor.
Food sensitization was the most significant predictor of
eczema at age 1 (OR¼2.73, 95% CI: 1.03–7.23, P¼0.04).
Table 3. Associations of CD14 C-159T and IL4Ra I75V SNPs with Eczema among CCAAPS Caucasians
Eczema at age 1 Eczema by age 3 Eczema at ages 2 and 3
SNP OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
CD14
C-158T
CC 2.25 (0.61–8.31) 0.36 1.47 (0.79–2.75) 0.06 3.01 (1.04–8.68) 0.01
CT 2.27 (0.66–8.01) 0.32 0.88 (0.48–1.60) 0.15 1.4 (0.49–4.00) 0.55
TT Ref. Ref. Ref.
IL4Ra
I75V
II Ref. Ref. Ref.
IV 1.47 (0.60–3.58) 0.40 1.77 (1.07–2.96) 0.03 1.87 (0.82–4.26) 0.13
VV 1.13 (0.31–4.07) 0.85 1.72 (0.85–3.47) 0.13 2.60 (0.94–7.19) 0.07
Combination of both SNPs
CC and IV/VV genotype 1.21 (0.49–3.01) 0.68 2.24 (1.27–3.94) 0.01 3.44 (1.56–7.57) o0.01
CCAAPS, Cincinnati Childhood Allergy and Air Pollution Study; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
Bold indicates Po0.05.
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DISCUSSION
In this study, we determined genetic and environmental
factors that contribute to the development of eczema in a
birth cohort. Our main findings are (1) a combination of
the CD14C-159T CC and IL4RaI75V IV/VV genotypes
increase the risk of eczema up to 3.5-fold; (2) dog exposure
significantly decreases eczema risk, even after adjustment for
parental eczema and gender; and (3) the protective effect of
dog ownership is most evident among carriers of the CD14
CT or TT genotype. Sensitization to food allergens in early
childhood is associated with the development of eczema, the
first step in the so-called ‘‘atopic march’’ that gives rise to
asthma and allergic rhinitis (Leung et al., 2004). Our data
support this as sensitization to a food allergen was observed
to be the greatest risk factor of eczema development by age 1.
The combination of CD14 and IL4Ra SNPs was strongly
associated with eczema, and the effect was strongest among
children who were SPTþ . This finding further highlights the
association of early-life aeroallergen as well as food sensiti-
zation and eczema. Recently, it has been suggested that
sensitization to allergens in children with eczema is
occurring through the skin and that this may predispose
children to the future development of asthma. Studies
evaluating the importance of the cornified envelope suggest
that damage to this barrier by genetic, physical, chemical,
and enzymatic compounds may allow allergens to cross
and interact with antigen-presenting cells, leading to allergic
sensitization and possible secondary development of asthma
(Hudson, 2006; McGrath and Uitto, 2008). Hence, sensiti-
zation through the skin (especially in the context of an
abnormal skin barrier) may promote the development of
asthma in later childhood. Our data support a strong
association between SPT and eczema. Children who were
SPTþ to at least one aeroallergen during the first three years
of life were over two times more likely to have eczema by age
3 and almost nine times more likely to have eczema at both
ages 2 and 3. This association supports the possibility that
children with eczema may initially be sensitized through
their skin, and cutaneous sensitization could then predispose
development of airway allergic disease.
Our data demonstrate that early-life exposure to dog may
be protective for eczema, as reported previously (Nafstad
et al., 2001; Holscher et al., 2002; Zirngibl et al., 2002; Gern
et al., 2004; Bufford et al., 2008). A pooled analysis of all
cohort studies in 2007 showed a 36% decrease in eczema
risk with dog exposure (Langan et al., 2007). Out of 11
cohort and cross-sectional studies, five reported significant
decreases in eczema risk, yet no significant increases were
observed, suggesting that dog exposure may be protective
against childhood eczema (Langan et al., 2007). Further, we
found that children who were exposed to dog and carried the
CT or TT genotype at CD14–159C/T had the lowest risk for
eczema at both ages 2 and 3. We also observed a borderline
gene–environment interaction between the CT genotype and
dog exposure in children aged 1 (P¼0.06; data not shown).
The literature on CD14 polymorphism and dog exposure
with respect to eczema has conflicting results. Our data agree
with the findings of Gern et al. (2004) who reported a
significant gene-by-environment interaction between the
CD14–589T TT genotype and dog exposure in children aged
1 (Gern et al., 2004). However, another study by Sengler
et al. (2003) found no association. The inconsistent findings
may be due to the presence of other environmental factors
that modify the relationship. CD14 is a pattern-recognition
receptor and binds bacterial lipopolysaccharide (Petersen
et al., 2007), lipoteichoic acid from Gram-positive bacteria
(Cleveland et al., 1996), peptidoglycans (Gupta et al., 1996),
mycobacteria, and viruses (Dobrovolskaia and Vogel, 2002;
Jiang et al., 2005), and mediates phagocytosis of apoptotic
cells without initiating inflammation (Devitt et al., 1998). The
protective effect of the CD14 C-159T allele against eczema
may be due to a protective effect conferred by CD14 ligands
such as endotoxin or other bacterial components. Dogs are
one of many sources of endotoxin in the house, and has been
reported with both dog presence and allergen level (Platts-
Mills et al., 2005). While there was a strong correlation
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Figure 2. C-589T, dog exposure and eczema. Unadjusted associations
between eczema and CD14 C-589T (a) and dog exposure (b), among
CCAAPS Caucasians. *Po0.05
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our cohort, we did not observe an independent association
between endotoxin and eczema (data not shown). Never-
theless, we did observe that the CD14 C-159T allele
combined with dog exposure was protective for eczema.
This incongruity might be due to a higher endotoxin level
surrounding the dog, producing an exposure ‘‘cloud’’ near
small children. Therefore, endotoxin levels measured from
home dust samples may not reliably reflect an individual
child’s exposure in their breathing zone. Alternatively, other
pathogen-associated molecular patterns acting through CD14
may be more relevant than endotoxin; thus, the protective
effects from dogs and endotoxin may work through different
mechanisms (Litonjua et al., 2002). We also observed a
significant interaction between the CD14-158C/T CC geno-
type and persistent aeroallergen sensitization among children
without dog exposure. These findings suggest that environ-
mental exposures (specifically dogs) can potentially block the
commencement of the atopic march in even very-high-risk
populations.
There are some important limitations of this study. One of
the limitations of birth cohort studies in general is that the
sample size may be underpowered. Furthermore, these
findings are not generalizable to the general population as
this cohort is comprised of infants born to at least one atopic
parent. However, the clinical outcomes of this study were
enriched because it is a high-risk cohort. Approximately 65%
of the children had a positive SPT reaction and 39% had
eczema during the first three years of life, enabling sufficient
sample size and power. Another limitation is the lack of
filaggrin data, the strongest known genetic predictor of
eczema. While these data are not available for the cohort
at this time, we plan to examine the impact of filaggrin in the
future. Finally, as with all parental reports of disease, eczema
history was subject to parental recall bias, which was
minimized by including questions from validated question-
naires and physician diagnosis in the outcome definition.
A major advantage of this study is that it was conducted in
a longitudinal birth cohort enabling comparisons in the same
individual at different time points in early childhood. Thus,
we were able to examine the development and recurrence of
eczema through age 3. Results obtained from birth cohort
studies are more reliable because they are less subject to
sampling selection and recall bias (Hunter, 2005; Manolio
et al., 2006). Birth cohort studies provide a more valid basis
for investigating genetics and environment since relevant
environmental exposures may occur in early infancy prior to
disease onset. Another unique advantage in CCAAPS is the
availability of quantified measures of exposure.
To the best of our knowledge, this is the first report
dissecting the effect of gene and environment on longitudinal
eczema and longitudinal allergen sensitization status in a birth
cohort. Larger population studies are warranted to determine
the potential clinical utility and predictive value of our results.
MATERIALS AND METHODS
Study participants
A cohort of 762 high-risk infants born to at least one atopic parent
from the Greater Cincinnati area was followed prospectively from
birth (Ryan et al., 2005; LeMasters et al., 2006). The recruitment
strategies for the CCAAPS has been described in detail elsewhere
(LeMasters et al., 2006). Briefly, birth certificates were used to
identify children born between 2001 and 2003. The families were
invited to participate based on the proximity of their home to traffic
sources. This study was approved by the Institutional Review Board
committees of Cincinnati Children’s Hospital Medical Center and
the University of Cincinnati. Written informed consent was obtained
from each participant’s parent or legal guardian prior to enrollment.
The investigations were conducted according to the Declaration of
Helsinki Principles.
When infants were approximately 6–7 months of age, parents
were screened for allergy symptoms and underwent SPTs for 15
aeroallergens (meadow fescue, timothy, white oak, maple mix,
American elm, red cedar, short ragweed, Alternaria, Aspergillus,
Penicillium, Cladosporium, dust mite mix, German cockroach, cat,
and dog), as well as positive histamine and negative saline controls.
All SPTs were performed with a bifurcated device (Accusets ALK
America, Round Rock, TX). A positive SPT was defined as having
X3mm wheal with erythema. Parents with one or more allergy
symptoms and a positive (þ ) SPT were enrolled (LeMasters et al.,
2006).
Outcome definitions
At ages 1–3, each participating child was examined by a clinician.
At each clinical exam, parent(s) provided a detailed medical history
and the child received full physical examination, including an SPT to
the same 15 aeroallergens and milk and egg. Children were defined
as SPTþ if they had at least one positive reaction to any allergen
at age 1, 2, or 3. Children that were positive to any allergen at both
ages 24 and 36 months were defined as having persistent SPTþ .
Eczema was defined by either a positive medical history or
physical examination. A positive medical history was defined as
parental report to the clinician that the child experienced ‘‘frequent
skin scratching’’ (question adapted from the well validated ISAAC
core questionnaire for eczema; Asher et al., 1995) and had redness
or red spots, raised bumps, and/or rough dry skin for 46 months.
A positive physical examination was defined as one of the following:
(1) the child’s skin showed evidence of atopic eczema (erythema,
papulation, exoriations, lichenification, and flexural distribution);
(2) the clinician reported that atopic dermatitis was probable or
definite; or (3) the clinician’s global assessment of skin disease was
rated as mild to very severe eczema.
Eczema by age 3 was defined as a positive medical history or
physician’s assessment at any time between birth and age 3. Eczema
at both ages 2 and 3 was defined as medical history or diagnosis of
eczema at both ages 2 and 3. Subjects with eczema and SPTþ to
aeroallergens at both ages 2 and 3 were defined as having atopic
eczema at both ages 2 and 3.
DNA collection and SNP genotyping
Genomic DNA was isolated from buccal swabs using the ZR
Genomic DNA II Kit from Zymo Research (Orange, CA). Seven SNPs
in four genes: CD14-159C/T (rs2569190), IL4Ra I75V (rs1805010),
IL4Ra E400A (rs1805011), IL4Ra C431R (rs1805012), IL4 C-589T
(rs2243250), IL13 C-1112T (rs1800925), and IL-13 R130Q (rs20541)
were genotyped using the Roche LightCycler. Primers and probes
were designed using the LightCycler software. Of these SNPs, the
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genotype frequencies of three (rs1805010, rs1805012, and
rs1800925) were not in Hardy–Weinberg equilibrium in Caucasians.
This finding was not unexpected because the CCAAPS birth cohort
was at high risk for atopy. Quality control was examined through re-
genotyping a subset (20%) of DNA samples; our genotyping error
rate was below 5%.
Environmental exposure assessments
The extensive environmental exposure assessment for the CCAAPS
cohort has been described previously (Ryan et al., 2005; Biagini
et al., 2006; Cho et al., 2006a). Briefly, parents provided detailed
smoking habits for each person living in the child’s home at the
time of the parent SPT. In addition, parental report of cat and/or
dog ownership was collected. House dust samples were collected
from the floor of the infant’s primary activity room during home
visits performed by trained personnel before the child’s age one
clinical exam. Endotoxin levels were quantified from the dust
samples using the Limulus Amebocyte lysate assay kit (Cambrex
Corporation, Walkersville, MD; Campo et al., 2006). Prevalence
of visible mold was indexed based on history of water damage,
signs of visible mold/water damage and its size, and moldy
odor (Meklin et al., 2004; Cho et al., 2006b). Children living
in homes having none of these were considered unexposed to
mold. Homes with high mold exposure had visible mold in one
room or a combined area of visible mold and water damage
X0.2m2 (Meklin et al., 2004). All other homes were categorized as
having low mold.
Each child’s average daily exposure estimates to elemental
carbon attributable to traffic, hereafter referred to as DEPs, was
measured from ambient levels of fine particulate matter with
aerodynamic diameter o2.5 mm (PM2.5) collected at 27 sampling
sites in the greater Cincinnati, OH, area. Source apportionment
methodology was used to develop a DEP signature profile and
estimates of DEP exposure were calculated using a land-use
regression (LUR) model (Kolluri et al., 1995; Hu et al., 2006; Ryan
et al., 2008). High estimates were defined as the top quartile
(X0.44mgm3).
Statistical analysis
Genotypes for each of the seven studied SNPs were examined for
deviation from Hardy–Weinberg equilibrium using the w2-test in both
the Caucasian and African-American groups. Effects of the SNP
genotype and environmental exposures OR and 95% CI on clinical
outcomes of eczema and positive SPT were estimated by logistic
regression. Multivariate models were implemented for the eczema
outcomes, adjusted for gender and parental history of eczema.
Backward selection was used with a conservative significance level
of 0.2 to stay in the model. The analyses were implemented in SAS
9.1 (SAS Institute, Cary, NC). Overall, a P-value of 0.05 was
considered statistically significant; Bonferroni correction was used to
adjust for multiple testing in results interpretation.
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